On January 29, 2019 Propanc Biopharma, Inc. (OTCQB: PPCB) ("Propanc"), a clinical stage biopharmaceutical company focused on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, reported that its Chief Executive Officer, James Nathanielsz, will be presenting at the 2019 BIO CEO & Investor Conference on Tuesday, February 12, 2019, at 9:45 am EST (Press release, Propanc, JAN 29, 2019, View Source [SID1234532944]). The conference will be held at the New York Marriott Marquis.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The BIO CEO & Investor Conference is one of the largest investor conferences, focused on established and emerging publicly traded and select private biotech companies, and I am honored to be selected to present at this year’s conference. As we prepare to transition our lead technology into human trials, this is a great opportunity for us to meet with investors and potential partners to provide a company update for 2019, focusing on the advancement of our lead product, PRP," said James Nathanielsz, CEO and Executive Chairman of Propanc. "PRP is a solution for intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen. Progressing towards a first-in-human study, PRP seeks to prevent recurrence and metastasis from solid tumors by targeting and eradicating cancer stem cells."
Investors and potential partners attending the conference who wish to meet with Propanc’s management can reach out through the BIO One-on-One Partnering system to request a meeting. For those not planning to attend the meeting, please contact Lisa DeScenza to set up a call with Mr. Nathanielsz to learn more about Propanc.
A live audio webcast of Mr. Nathanielsz’s presentation will be accessible within the Investor Relations section of Propanc’s website at View Source An archived version of this webcast will be available for 90 days following the conclusion of the live presentation.